Application of drug delivery technologies to enhance translational of experimental therapeutics
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Ferguson TEG
(2022)
Novel inhibitors and activity-based probes targeting serine proteases.
in Frontiers in chemistry
McBride J
(2019)
Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES
in International Journal of Pharmaceutics
| Description | Collaborative Awards in Science |
| Amount | £907,730 (GBP) |
| Funding ID | UNS39792 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2022 |
| Description | Engineering Centres of Excellence |
| Amount | £959,568 (GBP) |
| Organisation | Randox Laboratories |
| Sector | Private |
| Country | Global |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Healthcare Technologies |
| Amount | £821,430 (GBP) |
| Funding ID | EP/P034063/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 10/2020 |
| Description | Microneedle-mediated delivery of fixed dose combinations |
| Amount | £100,000 (GBP) |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Optimisation of microneedle insertion and understanding the implications of repeat application as tools to support translation |
| Amount | £1,240,247 (GBP) |
| Funding ID | EP/V047221/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2024 |
| Description | Program for appropriate technologies in health- Transdermal delivery of rilpivirine and gentamicin using microneedles |
| Amount | £200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Company Name | RE-VANA THERAPEUTICS LTD |
| Description | To develop and deliver transformative photocrosslinked sustained release biologics and small molecule drugs for the eye |
| Year Established | 2016 |
| Impact | · Spin out company created - Revana Ocular Limited - set up May 2016. NI638333. · Revana raised ~£1.2m seed investment from assorted institutional and private investors August 2017. · Priority patent application filed 10 November 2015 entitled 'ocular compositions' GB1519811.2. PCT application filed 10 November 2016. · Series A round of >£2M secured |
| Website | https://www.revanatx.com/ |
| Company Name | PHION THERAPEUTICS LTD |
| Description | pHion Therapeutics is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response. pHion's therapeutic vaccine programme is focused on viral infections as it evokes a strong interferon gamma response. We believe that the RALA vaccine technology marks the advent of a new generation of therapeutic vaccines that could clear infectious diseases on a global scale. In addition to therapeutic vaccines, RALA possesses unique traits that will offer significant value in both oncology (tumour specific delivery) and in ex vivo gene therapy (nanoparticle formulation for AAV manufacture) applications. |
| Year Established | 2017 |
| Impact | N/A |
| Website | https://www.phiontx.co.uk/ |
| Description | QUB-Lubrizol Seminar Series: Polyurethanes in Drug Delivery Applications (Belfast, hosted by Prof K Malcolm) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The first of two exploratory seminar events between Queen's University Belfast researchers and Lubrizol was held in Belfast in November 2015. Lubrizol presented on its technologies and products with particular emphasis on its growing drug delivery business and key Queen's University Belfast academic staff gave research presentations. This event defined research topics of mutual interest (specifically concerning the application of thermoplastic polyurethane polymers to drug delivery) in order to form a foundation for future research collaborations and funding applications. |
| Year(s) Of Engagement Activity | 2015 |